Business / Finance

RSS

Tianyin Pharmaceutical second quarter revenue decreases 3.3% to $17.6 million

Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for second quarter of the fiscal year 2013.

14 Feb 2013

Medgenics closes public offering of 5,600,000 shares of common stock and warrants

Medgenics, Inc., the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces yesterday's closing of an underwritten public offering of 5,600,000 shares of common stock and Series 2013-A warrants to purchase up to an aggregate of 2,800,000 shares of common stock.

14 Feb 2013

Targacept reports net loss of $15.9 million for fourth quarter 2012

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the fourth quarter and year ended December 31, 2012.

14 Feb 2013

Weight Watchers International fourth quarter revenues increase 1.7% to $407.9 million

Weight Watchers International, Inc. today announced its fiscal 2012 results for the fourth quarter and full year and provided full year fiscal 2013 earnings guidance.

14 Feb 2013

ArthroCare fourth quarter total revenue increases 4.9% to $96.9 million

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced its financial results for the fourth quarter and year ended December 31, 2012.

14 Feb 2013

Dyax fourth quarter total revenues increase to $16.0 million

Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2012.

14 Feb 2013

Antibody therapeutics targeting GPCRs to be developed by alliance between MorphoSys and Heptares

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, have signed an agreement to discover novel antibody therapeutics targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases.

13 Feb 2013

BioMed Realty Trust commences 11,500,000 stock offering

BioMed Realty Trust, Inc. today announced it has commenced a public offering of 11,500,000 shares of its common stock pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission.

13 Feb 2013

Pac-fico Salud and Johns Hopkins sign landmark affiliation agreement

World-class standards for clinical outcomes and patient safety are at the core of a landmark affiliation agreement signed today between Johns Hopkins Medicine International (JHI) and Pac-fico S.A. Entidad Prestadora de Salud (Pac-fico Salud), a Lima, Peru-based subsidiary of Credicorp Ltd.

13 Feb 2013

Fluidigm fourth quarter product revenue increases 25% to $15.4 million

Fluidigm Corporation today announced its financial results for the fourth quarter and full year ended December 31, 2012.

13 Feb 2013

Greenway fiscal 2013 second quarter revenue increases 12% to $32.7 million

Greenway Medical Technologies, Inc., which delivers innovative software and business services solutions for ambulatory care providers through its PrimeSUITE® platform, today announced financial results for the three months and six months ended December 31, 2012, as well as a revised outlook for results from operations for fiscal 2013.

13 Feb 2013

We Care Health Services acquires Pace Group of Companies

We Care Health Services (We Care), Canada's most trusted name in home health care and support services, is pleased to announce that it is further expanding its comprehensive health care portfolio with the acquisition of the Kitchener-Waterloo based Pace Group of Companies (Pace).

12 Feb 2013

MannKind fourth quarter total operating expenses increase to $33.5 million

MannKind Corporation today reported financial results for the fourth quarter and year ended December 31, 2012.

12 Feb 2013

Skilled Healthcare fourth quarter revenue increases 2.4% to $219.2 million

Skilled Healthcare Group, Inc. today announced its consolidated financial operating results for the three and twelve-month period ended December 31, 2012.

12 Feb 2013

Omega reports operating revenues of $95.0 million for fourth quarter 2012

Omega Healthcare Investors, Inc. today announced its results of operations for the three- and twelve-month period ended December 31, 2012. The Company also reported Funds From Operations ("FFO") available to common stockholders for the three-month period ended December 31, 2012 of $61.4 million or $0.55 per common share.

12 Feb 2013

STD Med, Pavilion announce joint investment to launch Saphena Medical

Pavilion Medical Innovations L.L.C. of Norwell, MA and STD Med, Inc. of Stoughton, MA are pleased to announce a joint investment to launch Saphena Medical, Inc., a new cutting edge medical device company focused on Endoscopic Vein Harvesting technologies.

12 Feb 2013

Unilife revenues decrease to $0.7 million for three months ended December 31, 2012

Unilife Corporation, a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended December 31, 2012, (the second quarter of Fiscal Year 2013).

12 Feb 2013

Brookdale fourth quarter total revenue increases 4.1% to $699.7 million

Brookdale Senior Living Inc. today reported financial and operating results for the fourth quarter and full year 2012.

11 Feb 2013

Landauer reports revenue of $36.7 million for first quarter 2013

Landauer, Inc., a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high quality medical consumable accessories, today reported financial results for its fiscal 2013 first quarter ended December 31, 2012.

11 Feb 2013

DW Healthcare Partners completes fundraising for third fund

DW Healthcare Partners, a healthcare-focused private equity firm, announced today that it has completed fundraising for its third fund, which has closed with $265 million of committed capital, exceeding its original target of $250 million.

11 Feb 2013